Last $7.72 USD
Change Today -0.08 / -1.03%
Volume 21.6K
CGIX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 12:34 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

cancer genetics inc (CGIX) Snapshot

Open
$7.76
Previous Close
$7.80
Day High
$7.93
Day Low
$7.69
52 Week High
02/20/14 - $20.95
52 Week Low
12/3/14 - $4.83
Market Cap
75.4M
Average Volume 10 Days
40.9K
EPS TTM
$-1.53
Shares Outstanding
9.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CANCER GENETICS INC (CGIX)

Related News

No related news articles were found.

cancer genetics inc (CGIX) Related Businessweek News

No Related Businessweek News Found

cancer genetics inc (CGIX) Details

Cancer Genetics, Inc., an early-stage diagnostics company, focuses on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis, and response to treatment of cancer. The company offers a range of services in various areas, including microarray based testing, a proprietary microarray tests for the detection of chromosomal abnormalities observed in chronic lymphocytic leukemia, small lymphocytic lymphoma diffuse large B-cell lymphoma, mantle cell lymphoma, and kidney cancer. It also provides molecular testing services, such as polymerase chain reaction, sequencing, and mutahine analysis to analyze DNA and RNA, as well as to follow progression of disease and response to therapy at the genetic level; and cytogenetics testing, a series of methods that analyze human chromosomes in order to identify malignancy. In addition, the company provides FISH testing, an analysis of abnormalities at the chromosomal and gene levels; and flow cytometry testing, an immuno phenotype analysis of specific markers inside cells. Further, it offers histology testing, a microscopic examination of stained tissue sections; cytology testing, a non-gynecological fluid preparation for microscopic evaluations; and IHC testing, an analysis of the distribution of tumor antigens in specific cell and tissue types. Additionally, the company provides various non-proprietary oncology-focused tests and laboratory services comprising molecular testing, sequencing mutational analysis, flow cytometry testing, histology testing, and cytology testing services to oncologists and pathologists in hospitals, cancer centers, and physician offices, as well as to biotech and pharmaceutical companies for their clinical trials. The company was founded in 1999 and is headquartered in Rutherford, New Jersey.

61 Employees
Last Reported Date: 03/28/14
Founded in 1999

cancer genetics inc (CGIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $649.0K
Vice President of Research & Development
Total Annual Compensation: $291.3K
Compensation as of Fiscal Year 2013.

cancer genetics inc (CGIX) Key Developments

Cancer Genetics, Inc. Presents at RedChip Global Online CEO Conference, Jan-28-2015 11:00 AM

Cancer Genetics, Inc. Presents at RedChip Global Online CEO Conference, Jan-28-2015 11:00 AM.

Cancer Genetics, Inc. Launches Digital Platform to Enable Collaboration with Community Hospitals and Laboratories

Cancer Genetics, Inc. announced the launch of their ExpandDx(TM) collaborative testing program. CGI's ExpandDx program, which utilizes VENTANA digital pathology technology from Roche, allows community-based hospitals and pathology labs to partner with CGI through remote consultations, and enables access to a broader range of tests that expand the clinical testing capabilities of community labs and hospitals. The technical-only testing service provides community hospitals and pathology labs with the most advanced testing technologies available, and facilitates increased collaboration on both atypical and difficult cancer cases. Through CGI's ExpandDx collaborative testing program, the technical component will be performed at CGI laboratories, and clinicians will have the option of interpreting and signing out their patients' test results. By allowing clinicians to sign out cases remotely and share cases with other team members, the program enables smaller labs to manage resources while still leveraging CGI's unique tests and expertise in oncology diagnostics.

Cancer Genetics, Inc. Receives Approval to Provide Oncology Testing for Patients in California

Cancer Genetics, Inc. announced that its CLIA-certified, CAP-accredited reference laboratory has received licensure from the California Department of Health. The California Clinical Laboratory License will allow the company to provide its oncology testing services for patient samples from the state of California.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CGIX:US $7.72 USD -0.08

CGIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $48.15 USD +0.0395
Genomic Health Inc $33.44 USD +1.06
NeoGenomics Inc $3.99 USD +0.02
Response Genetics Inc $0.45 USD +0.0291
Rosetta Genomics Ltd $3.07 USD -0.06
View Industry Companies
 

Industry Analysis

CGIX

Industry Average

Valuation CGIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.5x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CANCER GENETICS INC, please visit www.cancergenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.